Pilot Study of Rituximab and Brentuximab Vedotin With Deferred BMT for Relapsed Classical Hodgkin Lymphoma
Phase of Trial: Phase 0
Latest Information Update: 30 May 2016
At a glance
- Drugs Brentuximab vedotin (Primary) ; Rituximab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 17 May 2016 Brentuximab vedotin will be given for up to 10 doses (cycles) instead of 8 doses (cycles).
- 06 Jul 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 24 Jul 2013 New trial record